In Brief: Guidant
This article was originally published in The Gray Sheet
Executive Summary
Guidant: Receives expanded FDA approval of its balloon dilatation catheters for use in performing angioplasty during heart attacks, the firm says in a June 5 release. The expanded labeling is based on data from the Global Use of Strategies to Open Occluded Arteries II (GUSTO IIb) sub-study which was published in the June 5 New England Journal of Medicine. The study, by Stephen Ellis, MD, Cleveland Clinic, Ohio, et al., showed that balloon angioplasty "provides a small-to-moderate, short-term clinical advantage over thromboloytic therapy" with recombinant tissue plasminogen activator...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.